Search
Research
Blinatumomab Added to Chemotherapy in Infant Lymphoblastic LeukemiaKMT2A-rearranged acute lymphoblastic leukemia (ALL) in infants is an aggressive disease with 3-year event-free survival below 40%. Most relapses occur during treatment, with two thirds occurring within 1 year and 90% within 2 years after diagnosis. Outcomes have not improved in recent decades despite intensification of chemotherapy.
Research
Protocol for a systematic review of long-term physical sequelae and financial burden of multidrug-resistant and extensively drug-resistant tuberculosisMultidrug resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB) are major public health threats that are significant causes of physical sequelae and financial consequences for infected people. Treatment for MDR- and XDR-TB are more toxic and take longer duration than for drug-susceptible-TB. As a result, the long-term sequelae are thought to be more common among patients with MDR- and XDR-TB than drug-susceptible-TB, but this is yet to be quantified.
Research
Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in InfantsWhether vaccination during pregnancy could reduce the burden of respiratory syncytial virus (RSV)-associated lower respiratory tract illness in newborns and infants is uncertain.
Research
Psychometric Properties of the Polish Version of the Perth Emotional Reactivity ScaleThe Perth Emotional Reactivity Scale (PERS) is a 30-item self-report questionnaire that assesses the ease of activation, intensity, and duration of negative and positive emotions. Our study aimed to introduce and validate the Polish version of the PERS.
News & Events
Hep C can be cured, but many people are still not being treatedPeople living with hepatitis C in WA are being urged to take part in a new project, aimed at encouraging the take-up of treatment.
Thank you to our Sponsors Contact us If you'd like to get in touch, please contact Marie Nadal-Sims by phone or email. Phone: (08) 6319 1001 Email:
Contact us If you'd like to get in touch, please contact us by phone or email. Phone: 0400 450 240 Email: vtg@thekids.org.au Meningococcus (Neisseria
The Wesfarmers Centre is pleased to announce the successful applications for the 2017 Round 2 Wesfarmers Centre Seed Funding. The Wesfarmers Centre
Eight applicants were successful, and were awarded $15,000 each for activities supporting subsequent research grant applications.
In 2014, the Wesfarmers Centre of Vaccines & Infectious Diseases put out a first call for seed funding proposals.